# Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease

> **NCT01850238** · PHASE1 · COMPLETED · sponsor: **Axon Neuroscience SE** · enrollment: 30 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** AADvac1
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01850238
- **Lead sponsor:** Axon Neuroscience SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01850238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01850238, "Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01850238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*